COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children

Pediatr Infect Dis J. 2024 Apr 1;43(4):361-364. doi: 10.1097/INF.0000000000004206. Epub 2024 Jan 15.

Abstract

Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / complications
  • COVID-19* / prevention & control
  • Child
  • Clinical Trials as Topic
  • Cohort Studies
  • Humans
  • Parents
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome

Substances

  • COVID-19 Vaccines

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related